Skip to main content

Animations

MJFF Publications

1281 - 1290 of 8826 Results
Title
Year
  • Year
  • 2023
  • 2021
  • 2024
  • 2022
  • 2025
  • 2024
  • 2022
  • 2025
  • 2022
  • 2017
  • Summary Details
    OPEN
    Title: A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation
    Journal Name: Drugs
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s40265-023-01838-z
    Citation Count: 32
  • Summary Details
    OPEN
    Title: Systematic Review on Parkinson’s Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson’s Symptoms
    Journal Name: International Journal of Environmental Research and Public Health
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/ijerph19010364
    Citation Count: 67
  • Summary Details
    OPEN
    Title: Clearing the Smoke: What Protects Smokers from Parkinson's Disease?
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.29707
    Citation Count: 21
  • Summary Details
    OPEN
    Title: Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.28941
    Citation Count: 78
  • Summary Details
    OPEN
    Title: Positron Emission Tomography Imaging in Clinical Trials for Parkinson's Disease: Applications of Metabolic Brain Network Approach
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.30231
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Constructing and exploring neuroimaging projects: a survey from clinical practice to scientific research
    Journal Name: Insights into Imaging
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13244-024-01848-9
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Transcriptional landscape of human microglia implicates age, sex, and APOE‐related immunometabolic pathway perturbations
    Journal Name: Aging Cell
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1111/acel.13606
    Citation Count: 52
  • Summary Details
    OPEN
    Title: Radioligands Targeting the Purinergic P2X Receptors
    Journal Name: Cells
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/cells14130984
    Citation Count: 0
  • Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson’s disease
    2022
    Summary Details
    RESTRICTED
    Title: Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson’s disease
    Journal Name: Expert Review of Neurotherapeutics
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1080/14737175.2022.2091436
    Citation Count: 15
  • Summary Details
    OPEN
    Title: Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
    Journal Name: Molecular Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13024-017-0154-3
    Citation Count: 266
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.